Nicholas F. Evageliou

Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies

Nicholas F. Evageliou, Lindsay A. Renfro, Kelly Vallance, Carly R. Varela et autres

BACKGROUND: Improvements in therapy for patients with favorable histology Wilms tumor (FHWT) have relied on refinement of risk stratification for therapeutic assignment through identification of favorable and unfavorable prognostic factors. Although well established in International Society of Pediatric Oncology-Renal Tumor Study Group …

us, ca (code pays fourni par la source)

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors

Agustina Oller, Patrick Kemmeren, Daniela Perotti, Harm van Tinteren et autres

PURPOSE Molecular biomarkers are increasingly used for risk stratification, particularly in up-front surgery settings (Children's Oncology Group trials), whereas in preoperative chemotherapy setting, the ongoing International Society of Pediatric Oncology (SIOP)-Renal Tumor Study Group-2016 UMBRELLA study aims to validate selected biomarkers for …

nl, it, dk, ch, de, gb, us (code pays fourni par la source)

Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.

Agustina Oller, Patrick Kemmeren, Daniela Perotti, Harm van Tinteren et autres

Purpose Molecular biomarkers are increasingly used for risk stratification, particularly in up-front surgery settings (Children's Oncology Group trials), whereas in preoperative chemotherapy setting, the ongoing International Society of Pediatric Oncology (SIOP)-Renal Tumor Study Group-2016 UMBRELLA study aims to validate selected biomarkers for …

at, us (code pays fourni par la source)

A High‐Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK ‐Rearranged Non–Small Cell Lung Cancer

Alberto D. Guerra, Nicholas F. Evageliou, Vandana Batra, Kristen L. Dalton et autres

To the Editor: Pediatric lung adenocarcinoma is extremely rare, often presents with metastatic disease, and portends a poor prognosis with a median survival of 14 months and a 5-year survival rate of 26% [1-4]. Molecular diagnostics have become essential in pediatric non–small …

us (code pays fourni par la source)

AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy

Alix E. Seif, Sara McDonough, Emily M. Becker‐Haimes, Katelyn Oranges et autres

PURPOSE: Current care guidelines for children with AML recommend hospitalization during severe neutropenia. However, selected patients discharged before neutrophil recovery have similar chemotherapy course-specific bacteremia and mortality rates to those who remain hospitalized. On the basis of published literature, we developed a …

us (code pays fourni par la source)

Updated favourable-histology Wilms tumour risk stratification: rationale for future Children’s Oncology Group clinical trials

Daniel J. Benedetti, Nicholas G. Cost, Peter F. Ehrlich, Nicholas F. Evageliou et autres

us (code pays fourni par la source)

Associations of Patient Age, Tumor Nephrectomy Weight, and Tumor Diameter With Event-free and Overall Survival in Stage I or II Favorable Histology Wilms Tumor

Lindsay A. Renfro, Kelly Vallance, Ian Tfirn, Nicholas F. Evageliou et autres

OBJECTIVE: To evaluate age, tumor nephrectomy weight (TNW), or tumor diameter (TD) as continuous prognostic variables for outcomes in early-stage favorable histology Wilms tumor (FHWT) after accounting for biology and treatment. BACKGROUND: Patient age (<2 vs ≥2 years) and TNW (<550 g …

us, ca (code pays fourni par la source)

Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers

Daniela Perotti, Maureen J. O’Sullivan, Amy L. Walz, Jonathan J. Davick et autres

it, ie, us, gb, ca, nl, ch, de, br, fr (code pays fourni par la source)

Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532

Nicholas F. Evageliou, Lindsay A. Renfro, James I. Geller, Elizabeth J. Perlman et autres

INTRODUCTION: The prognostic impact of positive lymph nodes (LN+) and/or singular loss of heterozygosity (LOH) of 1p or 16q were assessed in children with stage III favorable histology Wilms tumor (FHWT) enrolled on AREN0532 or AREN03B2 alone. PATIENTS AND METHODS: A total …

us, ca (code pays fourni par la source)

Hallmark discoveries in the biology of Wilms tumour

Daniela Perotti, Richard D. Williams, Jenny Wegert, Jack Brzezinski et autres

it, gb, de, ca, br, se, pl, us, ch, nl, ie (code pays fourni par la source)

Supplementary Data (for publication) from Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression

Nicholas F. Evageliou, Michelle Haber, Annette Vu, Theodore W. Laetsch et autres

Supplementary Methods, Tables and Figures

Data from Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression

Nicholas F. Evageliou, Michelle Haber, Annette Vu, Theodore W. Laetsch et autres

Abstract Purpose: Deregulated MYC drives oncogenesis in many tissues yet direct pharmacologic inhibition has proven difficult. MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that antagonize polyamine sufficiency have synthetic-lethal interactions with MYC. Neuroblastoma is a …